Lipid Nanovesicles in Cancer Treatment: Improving Targeting and Stability of Antisense Oligonucleotides - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39967902/
Cancer remains a leading cause of mortality worldwide, accounting for approximately 10 million deaths annually. Standard treatments, including surgery, radiotherapy, and chemotherapy, often result in damage to healthy cells and...
Post-MI lipid management includes a discussion about LDL targets and use of high-dose, high-potency statins and behavioral/lifestyle changes to attain LDL goal. Reevaluation of lipids 3 months later commences with additional methods to lower LDL introduced then, as needed and this may include additional medications.
post mi, I am part of the team that gets consulted on lipid management as well as a nutrition consult is generated. If LDLc is not within guidelines of AHA or NLA ( at least less than 70 mg/dl) I add PCSK9i for LDLc normalization as well as plaque regression post MI leaving the maximally tolerated statin plus/minus ezetimibe on board .
